...
首页> 外文期刊>The Australian and New Zealand journal of psychiatry >Tailored treatment for depression with co-morbid dementia
【24h】

Tailored treatment for depression with co-morbid dementia

机译:用共同病态痴呆症定制治疗抑郁症

获取原文
获取原文并翻译 | 示例
           

摘要

Banerjee et al. (2011) have provided good news concerning treatment of depression when co-morbid with dementia. Their double-blind, placebo-controlled trial of sertraline and mirtazapine versus placebo showed a 38% reduction in mean score (from 13 to 8) on the Cornell Scale for Depression in Dementia (CSDD) (Alexopoulos et al., 1988) within 13 weeks, and the score was much the same at 39 weeks. However, the reductions were no greater in those treated with antidepressant than in the group given placebo. All participants had been referred to and treated by old age psychiatry teams. The authors concluded that antide-pressants given with the usual care provided by such teams are no more clinically effective than placebo.
机译:Banerjee等人。 (2011年)在与痴呆症持续治疗时,提供了有关抑郁症的好消息。 它们的双盲,安慰剂对照试验塞拉司汀与安慰剂,在痴呆症(CSDD)(Alexopoulos等,1988)中抑郁症的平均得分(从13至8)减少了38% 几周,39周的分数差不多。 然而,在给予安慰剂的抗抑郁药物处理的那些中,减少不较大。 所有参与者都被老年精神病学团队提交和治疗。 作者得出结论,通过这些团队提供的通常护理的抗灭弧剂在临床上没有比安慰剂更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号